ArticleBMJ open ophthalmology2025
Three-year outcomes of two-stage intra-Tenon low-dose mitomycin C injection versus sponge application in trabeculectomy.
Article in BMJ open ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThis retrospective comparative study evaluated the 3-year outcomes of two mitomycin C (MMC) delivery techniques in trabeculectomy for medically uncontrolled glaucoma: innovative two-stage intra-Tenon injection versus conventional sponge application, assessing efficacy and safety parameters.
methodsFrom January 2014 to December 2017, 110 eyes (55 intra-Tenon injections, 55 sponge applications) underwent standardised trabeculectomy by a single surgeon. Comprehensive evaluation included serial intraocular pressure (IOP) measurements, glaucoma medication requirements, surgical success rates (complete: IOP 5-21 mm Hg with ≥20% reduction without medications; qualified: with medications), needling interventions and complication profiles.
resultsAt the 3-year follow-ups, the intra-Tenon injection group demonstrated superior outcomes: significantly greater mean IOP reduction (from 31.51 to 12.8 mm Hg and from 29.02 to 15.02 mm Hg, respectively,
conclusionThe two-stage intra-Tenon MMC injection provides significantly better IOP control, reduced dependence on medications and more durable surgical outcomes than sponge application, with comparable safety, supporting its potential as the preferred method of MMC delivery in modern trabeculectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.